Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company dedicated to developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's mission is to design and deliver next-generation immunotherapies to optimize health outcomes for patients. Headquartered in London, United Kingdom, Tiziana Life Sciences also maintains a U.S. headquarters in Boston, MA.

The company's lead immunotherapeutic candidate is Foralumab (TZLS-401), a fully human anti-CD3 monoclonal antibody. Tiziana Life Sciences is primarily focused on developing Foralumab for intranasal administration to treat a range of conditions, including non-active Secondary Progressive Multiple Sclerosis (SPMS), Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). The pipeline also includes Anti IL-6R (TZLS-501) and Milciclib (TZLS-201).

Ivor Elrifi serves as the Chief Executive Officer, appointed in August 2024, while Gabriele Cerrone is the Executive Chairman and Founder. Recent notable developments include the publication of positive data demonstrating intranasal anti-CD3 antibody attenuates Long COVID neuroinflammation and improves cognitive function in April 2026, and new biomarker data for nasal Foralumab in na-SPMS patients in February 2026. The company actively presents its clinical pipeline at major industry conferences, such as the Jefferies London Healthcare Conference.